| 2026-08-05 | Press release | Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments |
| 2026-08-05 | Press release | Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-29 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-27 | Press release | Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer |
| 2026-07-27 | Press release | Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer – Severino joins Sarepta’s Board of Directors – Doug Ingram to retire from Sarepta |
| 2026-07-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-22 | Press release | Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results |
| 2026-07-22 | Press release | Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results |
| 2026-06-30 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-30 | Press release | Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® |
| 2026-06-30 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-30 | Press release | Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® – Accepted for review with target action date of February 28, 2027 |
| 2026-06-07 | Transcript | FY26 earnings call transcript |
| 2026-06-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-01 | Press release | Sarepta Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-06-01 | Press release | Sarepta Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-05-13 | Press release | Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 5/13/26 |
| 2026-05-13 | Press release | Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference |
| 2026-05-06 | Deck | First Quarter 2026 Financial Results |
| 2026-05-06 | Press release | Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments |
| 2026-05-06 | Press release | Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-22 | Press release | Sarepta Therapeutics to Announce First Quarter 2026 Financial Results |
| 2026-04-22 | Press release | Sarepta Therapeutics to Announce First Quarter 2026 Financial Results |
| 2026-03-31 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-31 | Press release | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-25 | Deck | Clinical Results and Plan Forward: SRP-1001 for Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) SRP-1003 for Myotonic Dystrophy Type 1 (DM1) |
| 2026-03-25 | Press release | Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 |
| 2026-03-25 | Press release | Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 |
| 2026-03-24 | Press release | Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 |
| 2026-03-24 | Press release | Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 |
| 2026-03-19 | Press release | Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® |
| 2026-03-19 | Press release | Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® – Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval |
| 2026-03-16 | Press release | Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne |
| 2026-03-16 | Press release | SRPT Press Release - ENDEAVOR cohort 8 Enrollment ()_updated |